Dec. 15 at 4:29 PM
Adaptive Biotechnologies announced two non-exclusive agreements with Pfizer that could be worth up to
$890 million. The deals include a target discovery collaboration to identify disease-specific T-cell receptors for rheumatoid arthritis and a separate data licensing agreement granting Pfizer access to Adaptive’s proprietary TCR–antigen datasets for research and development across multiple immunology applications.
Under the rheumatoid arthritis collaboration, Adaptive will lead target discovery, while Pfizer will handle development and commercialization of resulting therapies. Adaptive will receive an upfront payment and may earn additional development, regulatory, and commercial milestone payments. In the second agreement, Pfizer will license Adaptive’s TCR–antigen data to help train AI and machine-learning models, with upfront and potential recurring license fees, though financial terms were not disclosed.
$ADPT $PFE